Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)

被引：8

作者：

Giles, Francis J. ^{[1
]}

le Coutre, Phillip ^{[2
]}

Bhalla, Kapil N. ^{[3
]}

Ossenkoppele, Gert ^{[4
]}

Alimena, Giuliana ^{[5
]}

Haque, Ariful ^{[6
]}

Gallagher, Neil ^{[6
]}

Kantarjian, Hagop M. ^{[7
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA

[2] Humboldt Univ, Charite, Campus Virchow Klinikum, Berlin, Germany

[3] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33620 USA

[4] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[5] Univ Roma La Sapienza, I-00185 Rome, Italy

[6] Novartis, E Hanover, NJ USA

[7] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood.V110.11.1029.1029

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1029

引用

页码：311A / 312A

页数：2